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Purpose. Hypomelanosis of Ito (HI) is a skin marker of somatic mosaicism. Mosaic MTOR 
pathogenic variants have been reported in HI with brain overgrowth. We sought to delineate 
further the pigmentary skin phenotype, and clinical spectrum of neurodevelopmental 
manifestations of MTOR-related HI. 
Methods. From two cohorts totaling 71 patients with pigmentary mosaicism, we identified 14 
patients with Blaschko-linear and one with flag-like pigmentation abnormalities, psychomotor 
impairment or seizures, and a postzygotic MTOR variant in skin. Patient records, including 
brain MRI were reviewed. Immunostaining (n=3) for melanocyte markers and ultrastructural 
studies (n=2) were performed on skin biopsies. 
Results. MTOR variants were present in skin, but absent from blood in half of cases. In a 
patient (p.(Glu2419Lys) variant), phosphorylation of p70S6K was constitutively increased. In 
hypopigmented skin of two patients, we found a decrease in stage 4 melanosomes in 
melanocytes and keratinocytes. Most patients (80%) had macrocephaly or 
(hemi)megalencephaly on MRI. 
Conclusion. MTOR-related HI is a recognizable neurocutaneous phenotype of patterned 
dyspigmentation, epilepsy, intellectual deficiency, and brain overgrowth, and a distinct 
subtype of hypomelanosis related to somatic mosaicism. Hypopigmentation may be due to a 
defect in melanogenesis, through mTORC1 activation, similar to hypochromic patches in 




































































Hypopigmentation along Blaschko’s lines defines hypomelanosis of Ito (HI). Although in the 
initial description 1, extracutaneous findings were not reported, HI was later recognized as a 
neurocutaneous disorder, because of the frequency of brain involvement and epilepsy 2–4. 
Hemihypertrophy and additional developmental anomalies also appear to be more common in 
HI 5,6. In some patients, it may be difficult to determine whether the affected skin is 
hypopigmented or hyperpigmented 7, hence the name “pigmentary mosaicism”, encompassing 
both types of linear dyschromia 8. For hypopigmentation, the denominations “pigmentary 
mosaicism of the Ito type” or “linear hypomelanosis in narrow bands” have also been 
suggested 9. 
The genetic basis of HI is only partially understood. It has long been recognized as a hallmark 
of somatic mosaicism, since multiple non-recurrent mosaic chromosomal anomalies have 
been reported in patients with this clinical feature10,11. In contrast to chromosomal anomalies 
however, few mosaic single-gene anomalies have been reported in pigmentary mosaicism so 
far. In rare cases, mosaic activating MTOR pathogenic variants have been detected in the 
brain, blood or buccal swabs (Supplementary table 1), but in most patients, genetic testing 
was not performed on skin biopsy, and their functional consequences on skin pigmentation 
were not studied. 
Besides somatic mosaic MTOR pathogenic variants in brain tissue, germline MTOR 
pathogenic variants have been reported in patients with Smith-Kingsmore syndrome (OMIM 
#616638) (Supplementary Figure 1), which consists of intellectual disability with 
macrocephaly, ventriculomegaly, seizures and facial dysmorphism (mid-face hypoplasia, 
hypertelorism, downslanted palpebral fissures, depressed nasal bridge, thin upper lip, flat 
philtrum). 




































































variants clinically and genetically, we performed in-depth phenotyping in HI patients 
harboring mosaic MTOR pathogenic variants in the skin, including brain magnetic resonance 
imaging (MRI) and microscopic and ultrastructural skin analysis. We now provide further 
delineation of the cutaneous and neurodevelopmental spectrum associated with MTOR post-
zygotic pathogenic variants. 
 
MATERIALS AND METHODS 
Study subjects 
Patients were ascertained by clinical geneticists or dermatologists in 10 French centers (Dijon, 
Lille, Montpellier, Créteil, Paris-Trousseau, Rennes, Clermont-Ferrand, Reims, Paris-Robert-
Debré, La Réunion), as part of a nationwide collaborative effort for identification of genes 
involved in cutaneous mosaic syndromes. Inclusion in the cohort required presence of both 
cutaneous and extracutaneous manifestations. Inclusion criteria in the phenotype study 
consisted of skin or hair hypopigmentation in a mosaic pattern - linear, segmental, or flag-like 
- associated with any type of extracutaneous involvement, and presence of a postzygotic 
MTOR variant. Criteria of non-inclusion were diagnoses of Mendelian disorders of 
pigmentation, particularly Waardenburg syndrome and piebaldism, or hypochromic bands 
resulting from linear inflammatory conditions, such as lichen striatus or ILVEN 
(Inflammatory linear verrucous epidermal nevus). All clinical features were recorded on a 
clinical research form, and cutaneous images were centralized and reviewed at the 
coordination center by two experts (AS, PV). Cerebral MRI was performed at each center and 
centralized reading was performed by three other experts (CM, DR, LG).  
 
Next generation sequencing 




































































patients, and at University College London for two patients. Genomic DNA was extracted 
from blood, 5-mm punch biopsies of hypopigmented skin, cultured skin fibroblasts, buccal 
swabs and saliva specimens. Details on next generation sequencing are available in 
Supplementary Method.  
In-depth exome sequencing on whole skin biopsies and blood genomic DNA was initially 
performed in 31 patients with hypopigmented bands along Blaschko’s lines or segmental 
hypochromic patches, associated with various extracutaneous features (Flow diagram in 
Supplementary Figure 2). We found a mosaic MTOR pathogenic variant in the skin from one 
patient with hemimegalencephaly and severe epilepsy. Other patients carried a mosaic 
chromosomal abnormality (7 cases), a germline X-linked variant in TFE3 12,13 (1 case), a 
postzygotic variant in RHOA 14 (2 cases) or other candidate genes (4 cases), or remained 
negative (16 cases). Targeted deep sequencing of MTOR was subsequently performed on 
hypopigmented skin and/or blood DNA from 40 additional patients with Blaschko-linear 
hypopigmentation associated with epilepsy or intellectual deficiency who were subsequently 
ascertained (Supplementary Figure 2). 
 
Assessment of mTOR activation on cultured skin fibroblasts 
Fibroblasts were obtained from a skin biopsy of patients P03 and P12. The presence of 
c.4556C>T (p.(Ala1519Val)) and c.7255G>A (p.(Glu2419Lys)) substitutions was checked 
both by Sanger sequencing (ABI BigDye Terminator Cycle Sequencing kit (v.3.1) and an ABI 
3130 Genetic Analyzer, Applied Biosystems, Villebon-sur-Yvette, France), and TUDS, which 
allowed determination of variant allele fractions (VAFs). A mixed culture of non-mutant and 
MTOR-mutant skin fibroblasts (p.(Glu2419Lys), VAF = 40%), three wild-type control 
fibroblast cultures (C1, C2, C3), and mixed cultures of non-mutant and PIK3CA-mutant 




































































M018 (p.(Gln546Lys), VAF = 40%) and M032 (p.(His1047Arg), VAF = 30%) were studied. 
Cells were maintained at 37°C in a humidified incubator in DMEM supplemented with 10% 
FBS, 1,000 u/l penicillin, 0.1 g/l streptomycin, and 2 mmol/l L-glutamine. Amino acid 
deprivation procedures were conducted as previously described 15,16. 
 
Phosphorylation of AKT at residue 473 was assessed using a direct ELISA assay kit 
(InstantOne®, eBioscience, Cambridge, UK, Cat No 85-86042-253). Results were expressed 
relative to control levels and pooled; statistical analysis was performed using one-way 
ANOVA with Tukey’s post-hoc analyses. Phosphorylation of p70S6K at residue 389 was 
assessed by immunoblotting and antibody labeling by Calnexin (#2679) and p70S6Kthr389 
(#9234, Cell Signalling Technology, London, UK). Cell size was measured on 10,000 cells 
per run on an MS3 multi-sizer (Beckmann-Coulter), after incubation of fibroblasts with or 




Additional skin biopsies for optical and electron microscopy were obtained from patients in 
each center and standard FFPE skin sections were processed prior to centralized analysis. 
Immunoperoxidase staining was performed on FFPE sections from P12 (hypopigmented and 
normal skin), P05 and P06 (hypopigmented skin only) and two control FFPE sections from 
age-matched controls, using anti-MITF (#NCL-L-MITF, 1:500, Leica, Nanterre, France) and 
anti-MelanA (1:200; ab731; Abcam, Cambridge, USA) mouse monoclonal antibodies. 
Glutaraldehyde-fixed skin biopsies from P12 and P11 were prepared for electron microscopy 
following standard procedures. Ultrathin sections (120 nm-thick) were observed on a JEOL 




































































pictures taken using ES1000W Erlangshen CCD camera (GATAN, Elancourt, France). Stage 
I and stage IV melanosomes were counted in 15 melanocytes from biopsies taken from both 
normal (control) and hypomelanotic skin from patients P12 and P11, respectively. 
Melanosomes were counted in 50 basal layer keratinocytes for each sample. Statistical 




In one affected individual from the initial cohort of 31 patients (P12), exome sequencing on 
DNA from hypopigmented skin identified a de novo predicted missense p.(Glu2419Lys) 
(c.7255G>A) MTOR variant, present in 21 of 74 reads (28%), absent from blood-derived 
DNA from her unaffected parents (Supplementary Table 2). The variant was absent from 
GnomAD variant database, found to affect a highly conserved nucleotide and amino acid, and 
was predicted as likely deleterious in silico. TUDS of the MTOR kinase domain harboring the 
c.7255G>A substitution confirmed its presence in 29% of alleles in whole skin biopsy, and 
41% of alleles in cultured skin fibroblasts. The variant was nearly undetectable in blood (less 
than 1% of reads) (Figure 1).  
 
In the second cohort of 40 patients, this variation and ten additional postzygotic MTOR 
substitutions were identified in 14 unrelated patients (35.0%): p.(Lys1452Asn), 
p.(Cys1483Tyr), p.(Ala1519Val), p.(Ala1519Thr), p.(Glu1799Lys), p.(Thr1977Ile), 
p.(Ile2017Thr), p.(Ser2413Ile), p.(Leu2427Pro) and p.(Ile2501Phe). Hypomelanotic skin 
samples were available for further study in 13/15 individuals with mosaic MTOR variants, and 
normally pigmented skin DNA was also available in one patient (P02). Skin variant allele 




































































available in 12/15 individuals. MTOR variants were found in blood in 6/12 patients, with 
lower VAFs than in the skin, between 1% and 30% (median = 0%) (Figure 1, Supplementary 
Table 3). Recurrent MTOR hotspots were identified in nine patients: p.(Glu1799Lys), 
p.(Glu2419Lys), and p.(Ala1519Thr)/p.(Ala1519Val) in two patients, as well as 
p.(Thr1977Ile) in three patients. Overall, five variants (p.(Lys1452Asn), p.(Ala1519Thr), 
p.(Ala1519Val), p.(Ile2017Thr), p.(Ser2413Ile)) had never been reported previously.  
 
Both p.(Glu2419Lys) and p.(Ile2017Thr) MTOR variants were previously found to result in 
constitutive mTOR complex 1 (mTORC1) activity in vitro and in vivo 17,18. Primary skin 
fibroblasts from P12, with a variant allele fraction of 40%, were used to test p.(Glu2419Lys) 
mTOR activity by assessing AKT and p70 ribosomal protein S6 kinase (p70S6K) 
phosphorylation status 15,19 (Supplementary Figure 3). ELISA (Supplementary Figure 3a) and 
immunoblotting experiments (Supplementary Figure 3b) following amino acid deprivation 
showed increased levels of phosphorylated AKTser473 and p70S6Kthr389 in mutant cells as 
compared to controls. AKTser473 and p70S6Kthr389 phosphorylation levels were similar to those 
of skin fibroblasts harboring PIK3CA activating variants (Supplementary Figure 3). However, 
in amino acid-rich conditions, the p.(Glu2419Lys) MTOR mutant cells showed no constitutive 
activity, in contrast with PIK3CA mutant cell lines (Supplementary Figure 3c). We found no 
significant differences in median cell diameter between mutant and control cells 
(Supplementary Figure 3d). In comparison, in primary cultured fibroblasts harboring the 
p.(Ala1519Val) MTOR variant at very low levels (< 1%), phosphorylation was not increased 
at baseline or under amino acid deprivation. 
 
The 15 patients (10 females and 5 males) aged 1 - 30 years (median: 6 years), consisted of 13 




































































defined linear hypopigmentation along Blaschko’s lines, in a typical S-shaped, V-shaped or 
whorled pattern, more visible under Wood’s light, mainly located on the trunk and lower 
limbs, without lateral predominance (Figure 2, Supplementary Table 4). One additional 
patient did not have linear hypomelanosis, but instead a hypopigmented patch of scalp hair, a 
segmental cutaneous flag-like hypopigmented patch on his shoulder, and iris heterochromia. 
Woolly/curly hair was found in four patients, but no other anomalies of the integument or 
mucous membranes were noted. Since a decrease in melanocyte numbers and melanosome 
maturation has been reported in ash-leaf macules of tuberous sclerosis patients harboring loss-
of-function variants in TSC1 or TSC2, which encode upstream inhibitors of mTOR, we 
studied melanogenesis in patients with MTOR-related HI. Biopsies from hypomelanotic and 
normally pigmented skin in patients P05, P06, P11 and P12, showed fewer normal 
melanocytes per standardized field on Melan-A immunostaining as compared to controls 
(mean=15.8 melanocytes/field for control skins and mean=5.2 melanocytes/field in HI skins, 
p=2.6.10-9) (Figure 3). On hypomelanotic skin biopsies, MITF expression appeared normal, 
since anti-MITF labeling in epidermal melanocytes was unchanged (Figure 3). MITF labeling 
was either positive (P12) or absent (P05 and P06). We failed to identify downregulation of 
MITF in primary skin fibroblasts from one patient (data not shown). 
 
In patients P12 and P11, the number of stage IV melanosomes were markedly decreased in 15 
melanocytes from hypomelanotic skin (n=378 and n=282, respectively), as compared with 15 
melanocytes from normal skin (n=577 and n=362, respectively) (p=0.03 for P12 and 
p=0.0002 for P11) (Figure 4). Likewise, the stage IV/stage I melanosome ratio in melanocytes 
from hypomelanotic skin was reduced by 61.9% as compared to normal skin in patient P12, 
and by 87.3% in patient P11. Mean numbers of melanosomes per cell were also decreased in 




































































P12, and by 67.6% in patient P11 (p-value=8.2.10-16 and 3.8.10-15 for P12 and P11). 
 
Twelve patients had psychomotor impairment ranging from mild (first steps achieved at 20 
months) to severe (sitting position achieved at 6 years). All of them subsequently had 
intellectual deficiency (ID). Autism spectrum disorder was present in four patients, who also 
had ID. Eight patients had macrocephaly (OFC ≥ +3 SD), associated with unilateral body 
overgrowth in four of them. One patient had slightly elevated OFC (+2.5 SD). Six patients 
had normal OFC, one of them with hemihypertrophy, (Figure 5, Supplementary Table 4). 
Seizures were diagnosed in 10 patients, including two without ID (Figure 5, Supplementary 
Table 4). Among patients with seizures, only 5 had macrocephaly, whereas all 5 patients 
without epilepsy had macrocephaly. 
 
Brain MRI was performed in 10 patients: three with normal OFC and seven with 
macrocephaly. Among patients with macrocephaly, MRI showed normal symmetric brains 
without megalencephaly (normal lateral ventricles and pericerebral spaces) in four 
(Supplementary Table 4, Figure 2). Among the 10 patients who had seizures, MRI was 
performed in six and showed HMEG in all of them, either with normal OFC (<+3 SD, in three 
patients) or macrocephaly (OFC between +3 and +4 SD, in the three others). All six cases of 
HMEG were characterized on MRI by i) increased volume of the white matter, ii) absence of 
signal change – except in one case with bilateral frontal grey matter heterotopia – and iii) 
cortex thickening in two patients. HMEG was also associated with homolateral (four patients) 
or bilateral (one patient) narrowing of lateral ventricle frontal horns, homolateral enlargement 
of the thalamus and caudate nucleus (one patient), or homolateral enlargement of cerebellum 
hemispheres (four patients). In the five patients without epilepsy, MRI was performed in four 




































































patients in our series (80%) had either macrocephaly or HMEG/MEG. 
 
Facial dysmorphism (Figure 5, Supplementary Table 4) consisted of hypertelorism, prominent 
forehead, depressed nasal bridge, or downslanting palpebral fissures. In addition to iris 
heterochromia in two cases, ocular involvement consisted of strabismus/amblyopia, 
astigmatism, myopia, hypermetropia, coloboma or retinitis pigmentosa. Renal anomalies 
usually found in TSC (angiomyolipomas and renal cysts) were absent in patients with mosaic 
MTOR pathogenic variants. On ultrasonography, 2/12 patients had increased renal cortex 
echogenicity, a non-specific finding. 
 
DISCUSSION 
In this group of 71 patients with patterned dyspigmentation, we identified a subset due to 
mosaicism for MTOR pathogenic variants. We have further delineated the clinical spectrum 
of MTOR-related hypomelanosis of Ito with neurodevelopmental anomalies (Supplementary 
Table 4). These features include intellectual deficiency, macrocephaly, hemimegalencephaly, 
epilepsy, in addition with a pigmentation pattern suggestive of mosaicism. This combination 
of neurocutaneous features has previously been reported (Supplementary Table 5) in seven 
patients with postzygotic MTOR activating pathogenic variants (Supplementary Table 1). Two 
reported siblings with a germline MTOR activating variant had a pigmentary phenotype 
without further description 20. 
 
The severity of neurodevelopmental phenotypes varied greatly among our patients. 
Intellectual functioning ranged from normal to severe ID. Patients without ID had epilepsy or 
megalencephaly. This neurodevelopmental spectrum overlaps with Smith-Kingsmore 




































































pathogenic variants with high VAFs in the brain 20. Presence of HI, absent in SKS patients 
with a constitutional heterozygous MTOR pathogenic variant, maybe an indication of 
mosaicism and the need for further studies. To date, intellectual disability (ID) has been 
reported in all patients with SKS or postzygotic MTOR pathogenic variants and HMEG. 
Severe ID was present in patient P15, who harbored a postzygotic p.(Ile2501Phe) change. In 
contrast, two individuals from one previously published family, who carried a germline 
p.(Ile2501Val) variant, had normal cognition, focal epilepsy and normal OFC 21. Since 
discrepancies in the cerebral phenotype for an identical germline variant cannot be explained 
by different amounts of mutant brain cells, the very mild phenotype in this family would be 
better explained by a milder gain-of-function effect of the p.(Ile2501Val) substitution than of 
the p.(Ile2501Phe) substitution that we found in a mosaic state in our patient. 
 
MRI showed HMEG in all six cases with seizures, whereas in four patients without epilepsy, 
MRI showed either megalencephaly (MEG) or a normal brain. This suggests that, in patients 
with postzygotic MTOR pathogenic variants, HMEG might be more epileptogenic than MEG. 
MRI did not show cortical or other cerebral malformations in the two MEG patients and in 
three of the HMEG patients, while only three patients with HMEG had focal cortex 
thickening suggestive of polymicrogyria or periventricular heterotopia. Hence, our series also 
supports that, in patients with a neurodevelopmental phenotype, HMEG or MEG without 
apparent brain malformation might be more suggestive of pathogenic variants in MTOR rather 
than in PIK3CA or AKT3, as previously outlined 22–25. Interestingly, the structure and function 
of homogeneously enlarged brains with postzygotic MTOR pathogenic variants may be less 
altered than of those with HMEG. Indeed, previous studies comparing phenotypes related to 
either postzygotic or germline MTOR pathogenic variants have suggested that severity of 




































































20,21,25. This is likely explained by increased strength of the gain-of-function effect of mosaic 
pathogenic variants, which would result in embryonic lethality in the germline state, as 
compared with a milder effect of germline pathogenic variants, which would be compatible 
with fetus survival. 
 
A pigmentary phenotype with hypopigmentation and hyperpigmentation has previously been 
reported in one of two sibs who both harbored a germline p.(Phe2202Cys) MTOR variant 20, 
but its precise clinical description is missing, and no conclusions can be drawn from this case 
about the role of germline MTOR pathogenic variants on skin pigmentation. All patients in 
our series carried postzygotic MTOR pathogenic variants in their skin, which were absent 
from blood in 50% of cases tested. Linear hypopigmentation has been considered a non-
specific manifestation of mosaicism, as various types of non-recurrent chromosome anomalies 
were initially reported in association with the phenotype, and some authors have even 
suggested that the term hypomelanosis of Ito should be abandoned 11. However, we and others 
have now found mosaic single gene defects in HI, such as MTOR or RHOA pathogenic 
variants 14. In one case of the phenotypic “opposite” of HI, linear and whorled nevoid 
hypermelanosis 26, where Blaschko-linear hyperpigmentation is the cardinal cutaneous 
feature, we have also described a pathogenic mosaic variant in the KITLG gene 27. Hence, 
hypo/hyperpigmentation along Blaschko’s lines should no longer be considered merely as a 
clinical marker of somatic mosaicism, since, in combination with extracutaneous findings, it 
may also specifically point at the causative gene. 
The MTOR gene encodes the mechanistic target of rapamycin (mTOR). This serine-threonine 
kinase is highly conserved, and is an essential component of MTORC1 and MTORC2 
complexes. The PI3K-AKT-mTOR signaling pathway is pivotal in cell growth, protein 




































































inconclusive, cutaneous hypopigmentation may directly result from mTOR complex 
hyperactivation. In tuberous sclerosis complex (TSC), a condition resulting from loss of 
function of TSC1 or TSC2 31, activation of mTOR has been shown to suppress melanogenesis 
via MITF downregulation, resulting in typical ash-leaf or confetti-like hypopigmented 
macules 32–34. Repigmentation can be obtained by treatment with topical mTOR inhibitor 
rapamycin 35, since mTORC1 inhibition results in induction of melanogenesis through 
upregulation of MITF and its downstream targets TRP1 and TRP2 32,33,36,37. In 
hypopigmented skin of four patients with MTOR-related HI, we found a decrease in 
melanocytes, a defect in the maturation process of melanosomes, and a reduced number of 
melanosomes in keratinocytes, as well as activating MTOR variants and increased AKT and 
p70S6K phosphorylation in dermal fibroblasts from patients. Our findings are consistent with 
upregulation of mTORC1 resulting in partial suppression of melanogenesis. Paradoxically 
though, in P02, normally pigmented skin harbored a VAF of 25%, whereas the VAF was only 
10% in hypopigmented skin. We hypothesize that lower VAFs may result from death of 
mutant cells in hypopigmented areas through autophagy, as recently shown in TSC 33. A 
decreased number of melanocytes was found both in hypopigmented and normal skin in P12 
(Figure 3), which supports this hypothesis.  
 
Our results highlight the diagnostic importance of accurate clinical phenotyping of mosaic 
syndromes, and provide further evidence that genetic defects underlying hypomelanosis of Ito 
extend beyond chromosomal mosaicism. Additional genetic defects remain to be identified in 
a number of patients with linear hypopigmentation and various associated manifestations. Yet, 
identification of mosaic MTOR pathogenic variants in hypomelanosis of Ito with 
neurodevelopmental defects defines a clinically- and genetically-recognizable condition. It 




































































Most MTOR pathogenic variants, not found in the germline state, are thought to be embryonic 
lethal. Hence, the risk of transmission from a mosaic patient harboring this type of variant 
appears low or absent. However, transmission of non-lethal pathogenic variants, resulting in 
offspring with Smith-Kingsmore syndrome, is still possible. Although the positive predictive 
value of HI with neurodevelopmental anomalies for the diagnosis of MTOR somatic 
mosaicism is not yet known, in our series, MTOR pathogenic variants were found in more 
than one third (36.6%) of patients with HI and seizures. Likewise, macrocephaly and/or 
HMEG/MEG, found in 80% of cases in our series, appear as fairly specific, as they were 
absent from patients with mosaic RHOA pathogenic variants 14,38. Hence, in our opinion, such 
typical clinical presentation warrants MTOR sequencing by ultra-sensitive methods. DNA 
from the skin or other affected tissue is required for genetic testing, since the VAF is higher in 
skin (21%) as compared with blood (0%), where MTOR pathogenic variants are usually 
absent or at very low levels, close to NGS detection limit (1% at a depth of 1000X). Last, 
clinical consequences of mTORC1 upregulation, particularly neurological involvement, may 
be amenable to tailored treatment with mTOR inhibitors, although data on efficacy are 
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Figure 1. Distribution of post-zygotic missense MTOR variations. (a) Structure of mTOR 
protein including the HEAT (Huntingtin, Elongation factor 3, protein phosphatase 2A, and 
TOR1) repeat; FAT (FRAP, ATM and TRRAP) domain; FRB (FKBP12-rapamycin binding) 
domain; Kinase (serine-threonine kinase kinase) domain; FATC (FAT, FRAP, ATM and TRRAP 
carboxy-terminal) domain; and FIT (Found in TOR) domain. VAFs (%) are shown as pie charts 
with a maximum allele fraction of 50%. DS: Dark skin; LS: Light skin; B (red): blood. Variation 
details are summarized in Supplementary Table 3. (b) Distribution of VAFs in hypopigmented 
skin (LS, black dots) and blood (red dots), with median values. 
 
Figure 2. Left: Clinical pigmentary skin phenotype in two patients. (a, b) P11. (a) Unilateral 
linear and whorled hypopigmentation in multiple large bands with ragged border and sharp 
midline limitation on the abdomen. (b) Enhanced contrast on Wood’s lamp illumination. (c,d) 
P12. (c) Linear hypopigmentation in large bands on left lower limb. (d) Enhanced contrast on 
Wood’s lamp illumination. (e, f) Facial features of patients P09 and P11. Right: Brain MRI of 
subjects P01, P03, P10 and P12. a-c: P12. Left HMEG with altered ventricle shape (small 
frontal horn), enlarged left thalamus and caudate nucleus (a), slightly thickened cortical mantle 
and enlarged white matter with normal signal (b) and enlarged anterior corpus callosum (c). d-f: 
P03. Normal corpus callosum (d), small frontal horns (e, f), and mild overgrowth of the right 
cerebral hemisphere, with slight enlargement of the right posterior ventricle (c). g-i: P10. Normal 
corpus callosum on sagittal section (g), overgrowth of the right cerebellar hemisphere (h), right 
posterior ventricle enlargement, small frontal horn, increased white matter volume and thickened 
cortical mantle (i). (j-l) P01. Thickened corpus callosum (j), with symmetrical enlargement of 





































































Figure 3. Microscopy of paraffin embedded skin biopsies. (a) Numbers of melanocytes per 
field on whole skin sections from patients P05, P06 and P12 (patients: 6 fields; controls: 13 and 
24 fields); hematoxylin eosin (HE) staining). DS = Dark skin; LS = light skin. (b) HE staining 
from P06 hypomelanotic skin. (c) Subject P12. Melan-A immunohistochemistry on skin biopsy 
sections from pigmented skin (top) and hypomelanotic skin (bottom). (d) Subject P12. MITF 
labeling on biopsy sections from pigmented skin (top) and hypomelanotic skin (bottom). Scale 
bar: 100 µm. Melanocytes are shown by arrowheads.  
 
Figure 4. Ultrastructural study. (a) Melanosome maturation in melanocytes: Melanosome 
count in melanocytes on skin biopsy sections from pigmented (black) and hypopigmented area 
(white) in patients P12 (left) and P11 (right). Melanosomes were counted in 15 melanocytes. 
Upper bars: stage I melanosome. Lower bars: stage IV melanosomes (numbers at top of each 
bar). Ratio and total number of counted melanosomes are given at top and bottom of each figure. 
(b) Melanosome quantification in keratinocytes. Mean number of melanosomes per basal layer 
keratinocyte (n=50) (c) TEM of melanocytes at the basal epidermal layer in subjects P12 (a, 
b) and P11 (c, d). Melanosomes (arrows), in dark (a-c) and hypopigmented (b-d) areas. DS: Dark 
skin; LS: Light skin. 
 
Figure 5. Clinical features in HI individuals with MTOR postzygotic pathogenic variants. 
(a) Frequencies of neurological involvement and overgrowth. (b) Standard deviations for OFC 
(dark grey) and body height (light grey). (c) Frequencies of recurrent facial features. Percentages 
were calculated with the number of patients with available data as the denominator. MI: Mild; 














































































Exome capture and sequencing were performed at the Centre National de Génotypage (CNG, Evry, 
France) from 3 μg of genomic DNA for each patient sample. As a first approach, we performed deep 
exome sequencing on skin-derived and blood-derived DNA from 31 patients with pigmentary skin 
mosaicism, and blood from their parents. In subject P12, exome sequencing was performed on DNA 
obtained from a hypopigmented skin band (mean depth 200X), and blood-derived DNA from her 
unaffected parents (mean depth 80X). Data were processed as previously described 
1
. Variant locations 
are based on the human genome reference sequence GRCh37/hg19. The Genome Analysis Toolkit 
(GATK) v.2.6-4 was used for base quality score recalibration, indel realignment, and variant discovery 
2
. Candidate de novo events were systematically identified by focusing on protein-altering and splice-
site variants. We assessed the presence of the identified variants in public variant databases, namely the 
Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org/) and the Catalogue of 
somatic variants in cancer (COSMIC, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). 
Targeted deep sequencing was performed on all 57 coding regions of MTOR (reference accession 
LRG_734_t1). Sequences were amplified using custom intronic primers (sequences available on 
demand) and standard long-range PCR protocols. Libraries were prepared using the transposase-based 
Nextera XT DNA Sample Preparation kit (Illumina, Evry, France), and sequenced on a MiSeq 
instrument (Illumina, Evry, France) according to the manufacturer’s recommendations. 
Nucleotide-level conservation and impact of amino acid substitutions were assessed using Genomic 
Evolutionary Rate Profiling (GERP), Polyphen-2 (HumVar-trained model), and Combined Annotation-
Dependent Depletion (CADD) scores. All prediction scores are listed in Supplementary Table 3. 
Exome and targeted deep sequencing were performed according to standard protocol (detailed in 
Supplementary data). All MTOR variants identified were submitted to the CLINVAR database under 
Supplementary  (Appendix, online only material, etc.)
2/14 
the number SUB8228199. 
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Supplementary Table 1. Previously reported MTOR variants in affected individuals with pigmentary 
features. 
 








Amino acid change 
chr1:g.11217231A>G Somatic p.(Cys1483Arg) Hemimegalencephaly, hypomelanosis of Ito Lee JH et al 2012 
3
 
 Somatic  Macrocephaly, ID, facial dysmorphism, 
linear hyperpigmentation  







p.(Thr1977Lys) Three unrelated patients with diffuse 
asymmetric MEG and hypomelanosis of Ito 
One patient with MEG, asymmetric 
polymicrogyria, hypotonia, and 
hyperpigmentation 




Handoko M et al, 2019 
6
 
chr1:g.11184612T>G Germline p.(Phe2202Cys) Two siblings with macrocephaly, severe ID, 
capillary malformations (face and shoulder) 
and area of hypo/hyperpigmentation 
Gordo G et al, 2018 
4
 
chr1:g.11184573G>A Somatic p.(Ser2215Phe) One patient with HMEG, severe ID, 
seizures, hypochromic patches 
Pelorosso C et al, 2019 
7
 
*Variant locations are based on GRCh37/hg19 and reference MTOR accession LRG_734_t1. 
MEG: megalencephaly; FCD: Focal Cortical Dysplasia; ID: Intellectual Disability; HMEG::hemimegalencephaly. 
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Supplementary Table 2. Summary of exome sequencing experiments in subject PED1004 and her 
unaffected parents 
 





















PED1004 Skin biopsy 51 20.798 
 
242 96.5 81.6 
Father Blood 51 9.498 
 
130 96.0 56.5 
Mother Blood 51 7.035 
 
91 95.2 37.5 
Mb, megabases; Gb, gigabases. 
a
Target size of the SureSelect Human All Exon V5 kit (Agilent). 
b
Bases from 
“Passing Filter” (PF) reads mapped to the human genome reference sequence (GRCh37/hg19 build of UCSC 
Genome Browser, see http://genome.ucsc.edu/). 
c
Sequencing depth metrics were calculated using RefSeq coding 




Supplementary Table 3. Summary of mosaic MTOR changes  































































COSM4140746 0/246,180 5.82  0.99 21.60 
CADD, Combined Annotation-Dependent Depletion; COSMIC, Catalogue of somatic mutations in cancer; 
Gnomad: Genome Aggregation Database; GERP, Genomic Evolutionary Rate Profiling 20–22.  
Presence of identified MTOR variants was assessed in several public variant databases, including dbSNP build 
141, Gnomad Browser, and COSMIC. All variants were absent from dbSNP build 14, and Gnomad database. 










P01 P02 P03 P04 P05 P06 P07 P08 P09 P10 P11 P12 P13 P14 P15 
Age* (Y) 
  
12 3 27 7 3 6 9 4 2.5 2.5 7 14 5.5 1 30 
Sex 
  
F M M M  F  F F F F M M F F F F 
Hypomelanosis  
  
Linear Linear Linear Linear Linear Linear Linear Linear Linear Flag-like Linear Linear Linear Linear Linear 
  Trunk (P) (R),  
lower limbs 
R side Upper limb (L) Lower limb (L 
+ R) 
Diffuse (trunk, 
upper + lower 
limbs) 
Diffuse (upper 





upper + lower 
limbs (L + R) 
Trunk, (P), 
limbs 
Upper limb (L), 





Lower +, upper 
limbs (L) 




Iris heterochromia - - - - - - - - - + - - - - + 
Unilateral overgrowth 
  
Lower limbs R - - - - - Lower limbs R Lower limbs - L - - - 
Macrocepha
ly 




ID + +  ++ - - ++ - +++ + ++ +++  +++ +++ + +++ 
ASD - - - - - - - + - - - + + - + 
Epilepsy - +  + + - - + - - + + + + + + 
Brain MRI Phenotype MEG HMEG (R) HMEG (R) NA N N NA NA MEG HMEG (R) Mild HMEG 
(R) 
HMEG (L) NA HMEG (R) NA 
 Asymmetry of 
LV  
- (narrow FH of 
both LV) 
Narrow FH of 
R LV 
Narrow FH of 
R LV 
  - -   - Narrow FH of 
R LV 
- Narrow FH of 
L LV, enlarged 
L thalami and 
caudate nuclei 
-   
 Corpus 
callosum 










 WM volume Increased (both 
hemispheres)  
N Increased (R)   N N   N Increased (R) Increased (R)  Increased (L)   Increased (R)  
 WM signal N N N   N N   N N Bilateral frontal 
neuronal 
heterotopias 
N   N  
 Cerebral 
cortex 
N N N   N N   N Thick (R) N  L thick cortical 
mantle 
N   








  Asymmetry 
(R>L) 
  
Psychomotor impairment + +++ + - - ++ - +++ + + ++ +++ ++  ++ + 
Distal joint hyperlaxity - - + + - + - - + - + + - - - 
Hypertelorism 
  




+ - - + + - - + + - - - - + - 
Depressed nasal bridge 
  
+ + - - + + - + + - + - - + - 
Scalp hair 
  
Woolly Curly - - - - - - - - - - Sparse Woolly - 
Anteverted nares 
  
+ - - + - - - + + - - + - - - 
Teeth malposition 
  
- - - - - - - - - - + + - - + 
High forehead 
  
- + + + - - + + + + + + + + - 
Frontal bossing 
  
- + - - - - - + + - + - + - - 








thin upper lip 
Sandal gap Facial asymetry - Telecantus 
epicanthus 
-   - Thick upper 
lip, high-arched 
palate 
- - - - 
Ocular anomalies 
  
ND Suspected S H  -  -  - S, H, 
amblyopia 
A, myopia Coloboma ND RP  - - Left partial 
cataract 
MTOR variant  p.(Lys1452Asn) p.(Cys1483Tyr) p.(Ala1519Val) p.(Ala1519Thr) p.(Glu1799Lys) p.(Glu1799Lys) p.(Thr1977Ile) p.(Thr1977Ile) p.(Thr1977Ile) p.(Ile2017Thr) p.(Ser2413Ile) p.(Glu2419Lys) p.(Glu2419Lys) p.(Leu2427Pro) p.(Ile2501Phe) 
VAF (HI)  27% 10% 16% 14% ND 27% 11% 40% ND 10% 23% 29% 21% 25% 19% 
VAF (Blood)  15% - - ND 30% ND - 1% 4% 1%  -  -  -  -  - 
* :at last examination, Y: year, ID: intellectual disability, ASD: autistic spectrum disorder; MEG:megalencephaly; HMEG:hemimegalencephaly; WM: white matter; ND: not determined; FH: Frontal horn; R: right-sided; L: left-
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Ocular anomalies Other features 
(Peserico et al. 1988)8 + HMEG, LV abnormal shape + + - Divergent strabismus - 
(Battistella et al. 1990)9 + 
HMEG, LV abnormal shape, abnormal 
periventricular WM signal 




(Battistella et al. 1990)9 + 
HMEG, abnormal periventricular WM 
signal 
- - - Divergent strabismus 
Facial dysmorphism, 
dysondotiasis 
(Williams and Elster 1990)10 + 
HMEG, abnormal periventricular WM 
signal 
- + + 
Optic nerve abnormality, 
retinal detachment, cataract 
Imperforate anus, colon 
atresia, syndactyly 
clinodactyly, cleft palate, 
bilateral conductive hearing 
loss, facial asymmetry, dental 
anomalies 
(Malherbe et al. 1993)11 + 
HMEG, enlarged LV,  pachygyria, poor 
delineation grey-WM 
+ + - - - 
(Tagawa et al. 1994)12 + 
HMEG, cortical thickening, pachygyria, 
LV abnormal shape, poor delineation 
grey-WM 
+ - - Hypo-pigmented iris - 
(Steiner et al. 1996)13 + 
HMEG, LV abnormal shape, poor 
delineation grey-WM 
+ + - - Hemiparesis 
(Auriemma et al. 2000)14 + 
HMEG, cortical thickening, pachygyria, 
LV abnormal shape 
+ Unknown + - Hypotonia 
(Chapman and Cardenas 2008)15 + HMEG + + - - - 
(Sharma et al. 2009)16 + HMEG, cortical thickening + + + - - 
(Assogba et al. 2010)17 + 
HMEG, calcifications in caudate and 
lentiformis nuclei 
+ + + - Mild liver enlargement 
(Lee and al, 2012)3 + 
HMEG, cortical dysplasia, ectopic and 
cytomegalic neurons 
 - Unknown Unknown Unknown Unknown 
(Okanari et al. 2014)18 + 
HMEG, right FCD, enlargement right 
cerebral hemisphere 
+ + - Unknown Hypotonia 
(Cuddapah et al, 2015)19 + 
HMEG, unilateral enlargement of left 
parietal and occipital lobe  
+ + - - - 
(Pelorosso et al. 2019)7 + 
HMEG, enlarged ventricles, brain midline 
rightward deviation, cortical thickening, 
abnormal WM signal 
+ +  -  -  - 








Supplementary Figure 1. Schematic representation of MTOR protein structure with 
previously reported germinal (light gray) and somatic variants (black)
3–7,23–29
. FAT: 
FRAP-ATM-TRRAP domain ; FRB : FKBP12-Rapamycin Binding domain ; FATC: C-




Supplementary Figure 2. Next generation sequencing approach in patients with 









 phosphorylation in 
MTOR mutant cell lines following amino acid deprivation (a-b), without amino acid 
deprivation (c) and cell size in MTOR mutant cell lines (d). (a) ELISA based evaluation of 
AKT
ser473
 phosphorylation following 50 minutes of amino acid deprivation in wild type 
control dermal fibroblasts (Cntrls, n=3), PIK3CA mutant fibroblast cell lines (n=4 with 
respective variant allele fractions; M020 [p.(Gly1049Arg) / 40%], M098 [p.(Glu418Lys) / 
32%], M018 [p.(Gln546Lys) / 40%] and M032 [p.(His1047Arg) / 30%]) and MTOR mutant 
fibroblast cell lines p.(Glu2419Lys) (VAF = 40%) and p.(Ala1519Lys) (VAF < 1%). Skin 
fibroblasts from patients with PIK3CA variants were used as positive controls. Data is pooled 
from three independent experiments and error bars represent standard error of the mean 
(SEM). **** p < 0.0001 One-way ANOVA, Tukey’s post-hoc analyses. (b) Western blot of 
p70S6K phosphorylation with or without 50 minutes of amino acid deprivation of control 
wild type cells (C1-C3), a PIK3CA mutant cell line (M18, p.(Gln546Lys) 40%) and two 
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MTOR mutant cell lines (p.(Glu2419Lys) and p.(Ala1519Val)). Representative of four 
independent experiments; calnexin has been used as a loading control. (c) ELISA based 
evaluation of AKT
ser473
 phosphorylation without amino acid deprivation in wild type control 
cells (Cntrls, n=3), PIK3CA mutant cell lines (n=4 with respective pathogenic variation 
burdens; M020 [p.(Gly1049Arg) 40%], M098 [p.(Glu418Lys) 32%], M018 [p.(Gln546Lys) 
40%] and M032 [p.(His1047Arg) 30%]) and MTOR mutant cell lines p.(Glu2419Lys) (40% 
pathogenic variation burden) and p.(Ala1519Lys) (<1% pathogenic variation burden). Data is 
pooled from three independent experiments and error bars represent SEM. **p < 0.01 One-
way ANOVA, Tukey’s post-hoc analyses. (d) Median cell diameter using a FACS-based 
multi-sizer with or without amino acid deprivation for 50 minutes. Pathogenic variation 
burdens are indicated below. Error bars represent SEM; 10,000 cells were counted in total. 
Skin fibroblasts from patients with known activating PIK3CA variants were used as positive 
controls and cultured primary fibroblasts carrying p.(Ala1519Val) pathogenic variation were 
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